- Home
- ASND vs PCVX Comparison
ASND vs PCVX Comparison
Compare ASND & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- PCVX
- Stock Information
- Founded
- ASND 2006
- PCVX 2013
- Country
- ASND Denmark
- PCVX United States
- Employees
- ASND N/A
- PCVX N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- ASND Health Care
- PCVX Health Care
- Exchange
- ASND Nasdaq
- PCVX Nasdaq
- Market Cap
- ASND 9.9B
- PCVX 9.6B
- IPO Year
- ASND 2015
- PCVX 2020
- Fundamental
- Price
- ASND $151.43
- PCVX $32.23
- Analyst Decision
- ASND Strong Buy
- PCVX Strong Buy
- Analyst Count
- ASND 14
- PCVX 9
- Target Price
- ASND $201.79
- PCVX $140.88
- AVG Volume (30 Days)
- ASND 409.7K
- PCVX 2.0M
- Earning Date
- ASND 05-01-2025
- PCVX 05-07-2025
- Dividend Yield
- ASND N/A
- PCVX N/A
- EPS Growth
- ASND N/A
- PCVX N/A
- EPS
- ASND N/A
- PCVX N/A
- Revenue
- ASND $376,478,932.00
- PCVX N/A
- Revenue This Year
- ASND $61.43
- PCVX N/A
- Revenue Next Year
- ASND $73.07
- PCVX N/A
- P/E Ratio
- ASND N/A
- PCVX N/A
- Revenue Growth
- ASND 36.34
- PCVX N/A
- 52 Week Low
- ASND $111.09
- PCVX $30.12
- 52 Week High
- ASND $169.37
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- ASND 47.14
- PCVX 13.91
- Support Level
- ASND $143.81
- PCVX $30.12
- Resistance Level
- ASND $161.91
- PCVX $76.61
- Average True Range (ATR)
- ASND 6.32
- PCVX 3.53
- MACD
- ASND -1.66
- PCVX -3.57
- Stochastic Oscillator
- ASND 29.81
- PCVX 4.54
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.